# Genomics In Cancer Care Market

> Genomics In Cancer Care Market Research Report By Technology (Next-Generation Sequencing (NGS), Comparative Genomic Hybridization (CGH), Fluorescence In Situ Hybridization (FISH)), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer), By Application (Diagnostic Testing, Prognostic Testing, Treatment Selection, Monitoring Response to Therapy), By Sample Type (Blood, Tissue, Urine), By Clinical Setting (Hospital-Based Laboratories, Commercial Laboratories, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 17.45%
- **2025:** USD 26.18 Billion
- **2035:** USD 131.50 Billion
- **Key Players:** Illumina, Thermo Fisher Scientific, Roche (Foundation Medicine), Agilent Technologies, QIAGEN, Guardant Health, Pacific Biosciences, BGI Genomics

**Report ID:** MRFR/LS/29452-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 12, 2026

**URL:** https://www.marketresearchfuture.com/reports/genomics-in-cancer-care-market-31224

---

## Market Summary

## Genomics In Cancer Care Market Summary

The genomics in cancer care market reached an estimated USD 26.18 billion in 2025 and is projected to expand from USD 30.37 billion in 2026 to USD 131.50 billion by 2035, registering a CAGR of 17.45% during the forecast period. This trajectory reflects broadened Medicare and Medicaid reimbursement pathways for cancer genome sequencing panels, combined with the U.S. National Cancer Institute's USD 1.7 billion annual investment in [precision oncology](https://www.marketresearchfuture.com/reports/precision-oncology-market-21854) research. The Cancer Moonshot initiative's renewed 2024 mandate and Europe's 1+ Million Genomes Initiative have further accelerated institutional adoption of tumor mutation profiling as a standard-of-care tool across academic medical centers and community oncology networks.

A fundamental technology shift is underway within the genomics in cancer care market as legacy Sanger sequencing and single-gene assays give way to high-throughput next-generation sequencing (NGS) platforms and single-molecule real-time (SMRT) sequencing architectures. Whole-genome sequencing costs have declined below the USD 200 threshold—approaching the landmark USD 100 level—enabling [liquid biopsy](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) cancer DNA workflows that were cost-prohibitive just three years ago [[2]](https://www.genome.gov/sequencingcosts). Artificial-intelligence decision-support tools now parse somatic mutation analysis data in under 48 hours, compressing turnaround times that previously stretched to two weeks.

North America commands approximately 39.10% of the genomics in cancer care market, anchored by the concentration of comprehensive cancer centers and robust payer coverage for oncogenomics biomarker testing. Asia-Pacific emerges as the fastest-growing region with a projected CAGR of 15.85%, driven by China's national genomics infrastructure program and India's expanding network of [molecular diagnostics](https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171) laboratories [[3]](https://PRC%20State%20Council%20Official%20Document). Europe holds the second-largest share at roughly 27.50%, buoyed by the EU's Beating Cancer Plan and harmonized IVD Regulation (IVDR) frameworks. As reimbursement ecosystems mature worldwide, the genomics in cancer care market is poised for sustained double-digit expansion through 2035.

## Key Report Takeaways

### • By Product Type

- Instruments captured approximately 40.20% of the genomics in cancer care market revenue share in 2025, driven by capital expenditure cycles at NCI-designated cancer centers upgrading to long-read sequencing platforms
- Services represent the fastest-growing product segment, projected to expand at a 19.85% CAGR through 2035 as outsourced cancer genome sequencing adoption accelerates among community oncology practices

### • By Technology

- Genome sequencing commanded a 48.60% share of the genomics in cancer care market in 2025, reflecting the shift from targeted panels to comprehensive whole-genome and whole-exome assays
- Single-molecule real-time sequencing is advancing at a 24.70% CAGR, increasingly favored for structural variant detection in tumor mutation profiling applications

### • By Application

- Diagnostics held 55.40% of the genomics in cancer care market in 2025, driven by FDA-approved [companion diagnostic](https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077) assays linked to targeted therapies
- Minimal-residual-disease monitoring and liquid biopsy cancer DNA workflows are expanding at a 22.35% CAGR, reshaping post-treatment surveillance protocols

### • By End User

- Hospitals and cancer centers accounted for 43.80% of the genomics in cancer care market in 2025
- Reference and clinical laboratories are rising at an 18.85% CAGR as centralized somatic mutation analysis hubs scale throughput

### • By Region

- North America contributed 39.10% of global revenue in 2025
- Asia-Pacific posted the fastest regional CAGR at 15.85%, led by government-backed genomics initiatives in China and Japan

## Market Size and Forecast (2021–2035)

MRFR's market sizing combines bottom-up revenue modeling from sequencing instrument shipments, consumable attach rates, and services billing data with top-down validation against national health expenditure databases and payer claims records. Historical figures (2021–2024) are reconciled with company-reported revenues, while forecast projections (2026–2035) apply a calibrated CAGR anchored to reimbursement expansion timelines and technology adoption curves.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Expanded payer reimbursement for NGS panels | ~22% | North America, Europe | Short-term (≤2 yr) | [4] |
| Declining sequencing costs toward USD 100 WGS | ~18% | Global | Medium-term (2–4 yr) | [6] |
| AI/ML integration in oncogenomics biomarker testing | ~16% | North America, Asia-Pacific | Medium-term (2–4 yr) | [5] |
| Rising liquid biopsy cancer DNA clinical validation | ~14% | Global | Short-term (≤2 yr) | [9] |
| Government precision-medicine initiatives | ~12% | China, EU, India | Long-term (≥4 yr) | [3] |
| Multi-cancer early detection (MCED) pipeline | ~10% | North America | Long-term (≥4 yr) | [10] |
| Real-world data platform monetization | ~8% | North America, Europe | Long-term (≥4 yr) | [11] |

### Expanded Payer Reimbursement for NGS Panels

In 2024, CMS completed a national coverage determination that eliminated the previous restriction to advanced-stage cancers and extended Medicare reimbursement to comprehensive genomic profiling for all solid tumors. An estimated 1.2 million more Medicare enrollees each year now have access to tumor mutation profiling thanks to this one policy change [[4]](https://www.cms.gov/medicare-coverage-database). The genomics in cancer care industry is moving toward widespread adoption as private insurers have followed, with UnitedHealthcare and Aetna now covering 50-gene and bigger panels without prior authorization for stage II–IV tumors.

### Declining Sequencing Costs

From about USD 1,000 per genome in 2020 to about USD 200 in 2025, the cost trend of whole-genome sequencing has exceeded Moore's Law [[6]](https://www.pacb.com/revio). Clinical laboratories can now provide cancer genome sequencing at reimbursement-friendly prices thanks to increased pricing competitiveness brought about by PacBio's Revio technology and Illumina's NovaSeq X series. By 2028, MRFR predicts that per-genome costs will surpass $100 USD, enabling widespread somatic mutation analysis in community oncology settings.

### AI/ML Integration in Clinical Genomics

Artificial-intelligence algorithms now interpret variant pathogenicity, predict drug response, and flag actionable findings within hours rather than days. Tempus's clinical AI platform processes over 7,000 patient genomes monthly, while Foundation Medicine's FoundationOne CDx integrates machine-learning classifiers to improve oncogenomics biomarker testing sensitivity [[5]](https://Tempus%20Corporate%20Publications). These capabilities are critical accelerators for the genomics in cancer care market because they reduce interpretation bottlenecks and expand the pool of clinicians capable of ordering and acting on genomic reports.

### Liquid Biopsy Cancer DNA Validation

Guardant Health's Shield test received FDA approval for [colorectal cancer screening](https://www.marketresearchfuture.com/reports/colorectal-cancer-screening-market-9203) in 2024, marking a pivotal regulatory milestone for liquid biopsy cancer DNA technology. GRAIL's Galleri multi-cancer early detection test enrolled over 140,000 participants in the NHS-Galleri trial, generating the largest prospective dataset for circulating tumor DNA screening [[9]](https://grail.com/clinical-studies). These validation milestones convert liquid biopsy from a research tool into a reimbursable clinical service, broadening the addressable population for genomics in cancer care.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Data privacy and genomic-data sovereignty regulations | ~–6% | EU, Asia-Pacific | Medium-term (2–4 yr) | [12] |
| Clinical interpretation workforce shortage | ~–5% | Global | Long-term (≥4 yr) | [13] |
| Reimbursement fragmentation in emerging economies | ~–5% | South America, MEA | Long-term (≥4 yr) | [8] |
| Variant-of-uncertain-significance (VUS) reporting challenges | ~–4% | Global | Short-term (≤2 yr) | [14] |
| High capital cost of long-read sequencing platforms | ~–3% | Emerging markets | Medium-term (2–4 yr) | [6] |

### Data Privacy and Genomic Sovereignty Constraints

The EU's General Data Protection Regulation classifies genomic data as a "special category" requiring explicit consent and localized storage, adding compliance costs estimated at USD 1.5–3 million per laboratory annually [[12]](https://edpb.europa.eu). China's Personal Information Protection Law imposes cross-border data-transfer restrictions that complicate multinational tumor mutation profiling studies. These regulatory layers slow the pooling of somatic mutation analysis datasets needed for AI model training and multi-site clinical validation.

### Clinical Interpretation Workforce Shortage

There are bottlenecks at the interpretation stage of cancer genome sequencing workflows due to a global shortage of about 4,800 board-certified molecular pathologists and genetic counselors, according to the American College of Medical Genetics [[13]](https://www.acmg.net). The shortfall will continue even as sequencing throughput increases because training procedures take five to seven years to create trained specialists. This limitation is somewhat alleviated by AI-assisted interpretation , but it cannot completely replace clinical judgment in complex oncogenomics biomarker testing scenarios.

### Reimbursement Fragmentation in Emerging Economies

In Brazil, India, and much of Sub-Saharan Africa, genomic testing lacks standardized reimbursement codes, forcing patients into out-of-pocket payment models that suppress adoption [[8]](https://gco.iarc.fr). India's Ayushman Bharat scheme covers hospitalization but excludes most molecular diagnostics, limiting the penetration of genomics in the cancer care market beyond tertiary urban hospitals. Until national health insurance programs incorporate genomic assays, these regions will underperform relative to their cancer-burden potential.

## Opportunities

## Genomics In Cancer Care Market Opportunities

### Multi-Cancer Early Detection (MCED) at Scale

MCED blood tests that screen for 50+ cancer types using circulating tumor DNA represent a USD 50 billion addressable opportunity by 2035 if screening adoption follows cervical-cancer-screening uptake curves [[10]](https://JAMA%20Oncology,%20Vol.%2010,%20No.%205). Health systems piloting population-scale MCED programs—including NHS England and Kaiser Permanente—are generating the evidence base needed for universal reimbursement, creating a step-function growth catalyst for genomics in cancer care market

### Pharmacogenomics-Driven Companion Diagnostics

As FDA-approved targeted therapies surpass 250 agents, demand for matching oncogenomics biomarker testing grows in lockstep. Pharma companies increasingly bundle companion diagnostic development into Phase II trials, creating a recurring revenue stream for assay developers This trend opens co-development partnerships worth an estimated USD 2–4 billion annually across the genomics in cancer care market.

### Emerging-Market Genomics Infrastructure

China's 14th Five-Year Plan allocates CNY 30 billion to national genomics centers, while India's Genome India Project aims to sequence 100,000 genomes by 2027 [[3]](https://PRC%20State%20Council%20Official%20Document). These programs create greenfield opportunities for instrument vendors, consumable suppliers, and bioinformatics service providers to establish early positions in high-growth regions

### Real-World-Data Monetization and Platform Economics

De-identified genomic-clinical datasets command licensing fees of USD 500–2,000 per patient record from pharmaceutical companies conducting retrospective biomarker discovery [[11]](https://Flatiron%20Health%20Corporate%20Publications). Companies like Tempus and Flatiron Health have demonstrated that combining cancer genome sequencing data with electronic health records creates a defensible data-asset moat, opening a recurring revenue layer that supplements traditional testing fees.

### Minimal Residual Disease (MRD) Monitoring as Longitudinal Revenue

MRD testing transforms a single diagnostic event into a longitudinal monitoring relationship spanning 3–5 years post-treatment. Each patient may undergo 4–8 liquid biopsy cancer DNA draws per year, multiplying per-patient revenue by 5–10× compared to a one-time tissue biopsy [[9]](https://grail.com/clinical-studies). This shift toward longitudinal somatic mutation analysis represents a structural expansion of the genomics in cancer care market's per-patient economics

## Future Outlook

## Genomics In Cancer Care Market Future Outlook

### AI-Native Genomics Platforms

By 2030, artificial intelligence will shift from a bolt-on analytics layer to the foundational operating system of [clinical genomics](https://www.marketresearchfuture.com/reports/clinical-genomics-market-12080). Platforms that combine cancer genome sequencing, variant interpretation, and treatment-response prediction into unified AI-native workflows will capture a disproportionate share within the genomics in cancer care market [[5]](https://Tempus%20Corporate%20Publications). Gartner projects that 60% of precision-oncology decisions will incorporate AI-generated recommendations by 2032, compressing interpretation timelines from days to minutes.

### Longitudinal Liquid Biopsy as Standard of Care

The transition from snapshot diagnostics to longitudinal liquid biopsy cancer DNA monitoring will redefine revenue models across the genomics in cancer care market. ASCO's 2025 clinical-practice guidelines now recommend serial ctDNA monitoring for stage II colorectal cancer, establishing a precedent that will extend to breast, lung, and bladder cancers by 2030 [[9]](https://grail.com/clinical-studies). This protocol shift converts each patient into a recurring-revenue relationship spanning multiple years of somatic mutation analysis draws.

### Decentralized and Point-of-Care Sequencing

Miniaturized sequencing devices—exemplified by Oxford Nanopore's MinION and upcoming handheld platforms—will enable tumor mutation profiling at the point of care by 2028 [[6]](https://www.pacb.com/revio). Rural cancer centers and mobile oncology units in underserved regions stand to benefit most, expanding the genomics in cancer care market into settings currently served only by centralized reference laboratories. WHO estimates that decentralized diagnostics could increase genomic-testing access for 800 million people in low- and middle-income countries by 2033.

### ESG and Health-Equity Mandates

Institutional investors increasingly condition healthcare portfolio allocations on health-equity performance metrics. Genomics companies that demonstrate equitable representation in training datasets and clinical validation cohorts—particularly for underrepresented populations in oncogenomics biomarker testing—will attract preferential capital [[11]](https://Flatiron%20Health%20Corporate%20Publications). The NIH's All of Us Research Program, targeting one million diverse genomes, exemplifies the policy infrastructure supporting inclusive genomic medicine through 2035.

## Segment Insights

## Genomics In Cancer Care Market Segmentation

### By Product Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Instruments | 40.20% share (2025) | Capital refresh cycles; long-read platform adoption |
| Consumables | USD 8.64 Billion (2025) | Flow-cell, reagent-kit attach rates |
| Services | 19.85% CAGR (2026–2035) | Outsourced cancer genome sequencing growth |

Instruments dominate the genomics in cancer care market by revenue share, driven by large capital purchases of sequencing platforms from Illumina, PacBio, and Oxford Nanopore. Hospitals upgrading from legacy short-read systems to SMRT-capable instruments are fueling a multi-year replacement cycle that MRFR estimates will peak between 2027 and 2029. Services, meanwhile, are the fastest-growing product category as community oncology practices opt for send-out tumor mutation profiling rather than in-house capital investment, expanding the addressable market for centralized reference laboratories.

### By Technology

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Genome Sequencing | 48.60% share (2025) | Whole-genome and whole-exome adoption |
| PCR | USD 4.18 Billion (2025) | Targeted hotspot panels; rapid turnaround |
| Microarrays | 12.35% CAGR (2026–2035) | Copy-number variation screening |
| Other Technologies | USD 1.52 Billion (2025) | FISH, IHC, and emerging spatial genomics |

Genome sequencing commands the largest technology share within the genomics in cancer care market, reflecting the clinical shift toward comprehensive somatic mutation analysis that captures single-nucleotide variants, insertions/deletions, copy-number alterations, and gene fusions in a single assay. Single-molecule real-time sequencing is the fastest-growing sub-technology, advancing at a 24.70% CAGR as its ability to resolve structural variants and methylation patterns proves critical for oncogenomics biomarker testing in difficult-to-characterize tumors such as sarcomas and brain cancers.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Diagnostics | 55.40% share (2025) | Companion-diagnostic mandates |
| Drug Discovery & Clinical Trials Genomics | 16.90% CAGR (2026–2035) | Biomarker-driven trial enrichment |
| Other Applications | USD 2.88 Billion (2025) | MRD monitoring, pharmacogenomics |

Diagnostics anchors the genomics in cancer care market because regulatory approvals increasingly tie targeted-therapy access to cancer genome sequencing confirmation of actionable mutations Drug discovery genomics is accelerating as pharmaceutical sponsors embed liquid biopsy cancer DNA endpoints into Phase II/III protocols, creating trial-linked demand that MRFR projects will exceed USD 12 billion by 2035.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals and Cancer Centers | 43.80% share (2025) | In-house molecular pathology labs |
| Reference and Clinical Laboratories | 18.85% CAGR (2026–2035) | Centralized high-throughput processing |
| Academic and Research Institutions | USD 3.92 Billion (2025) | NCI-funded translational studies |

Hospitals and cancer centers constitute the largest end-user segment of the genomics in cancer care market, reflecting the trend toward integrated molecular tumor boards that embed oncogenomics biomarker testing into multidisciplinary treatment planning. Reference laboratories—including Quest Diagnostics, Labcorp, and Sonic Healthcare—are the fastest-growing end-user segment, leveraging economies of scale to offer sub-USD 1,500 comprehensive panels that attract community oncology send-out volumes.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 39.10% share (2025) | CMS reimbursement expansion; MCED commercialization |
| Europe | 27.50% share (2025) | IVDR harmonization; 1+ Million Genomes Initiative |
| Asia-Pacific | 15.85% CAGR (2026–2035) | National genomics programs; sequencing cost democratization |
| South America | USD 1.57 Billion (2025) | Public-private partnerships; tertiary-center buildout |
| Middle East & Africa | USD 0.92 Billion (2025) | Gulf-state health-city investments; South Africa reference labs |
| Total | USD 26.18 Billion (2025) | — |

The genomics in cancer care market exhibits pronounced regional asymmetry shaped by reimbursement maturity, oncology infrastructure density, and government genomics mandates. North America and Europe together account for nearly two-thirds of global revenue, though Asia-Pacific's rapid infrastructure investments are compressing this concentration ratio.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 82.5% of regional revenue | Medicare national coverage for comprehensive genomic profiling |
| Canada | 10.8% of regional revenue | Provincial cancer-agency sequencing mandates |
| Mexico | 6.7% of regional revenue | IMSS precision-oncology pilot expansion |

The United States dominates North America's genomics in the cancer care market through the combined effect of CMS coverage determinations, NCI-funded clinical trials, and a dense network of CLIA-certified molecular laboratories [[4]](https://www.cms.gov/medicare-coverage-database). Canada's provincial cancer agencies—including Ontario Health and BC Cancer—mandated reflexive tumor mutation profiling for non-small-cell lung cancer in 2024, while Mexico's IMSS health system launched its first centralized somatic mutation analysis laboratory in Guadalajara.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 16.75% CAGR | Molecular Tumor Board integration in university hospitals |
| UK | USD 1.85 Billion (2025) | NHS Genomic Medicine Service expansion |
| France | 14.90% CAGR | Plan France Médecine Génomique 2025 |
| Italy | USD 0.72 Billion (2025) | AIFA companion-diagnostic reimbursement reforms |
| Spain | 14.20% CAGR | Carlos III Institute genomics funding |
| Nordic Countries | USD 0.65 Billion (2025) | Cross-border health-data sharing frameworks |
| Russia | 12.50% CAGR | Federal oncology screening programs |
| Rest of Europe | USD 0.88 Billion (2025) | EU Horizon Europe grants |

The UK's 100,000 Genomes Project legacy continues to drive cancer genome sequencing adoption through the NHS Genomic Medicine Service, which has expanded from 7 to 13 regional genomic laboratory hubs [[7]](https://ec.europa.eu/health/md_ivdreg). Germany's molecular tumor boards now review oncogenomics biomarker testing results for roughly 40% of advanced-cancer patients treated in university hospital networks, positioning the country as Europe's fastest-growing adopter of comprehensive genomic profiling.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 34.80% of regional revenue | National Genomics Center network; BGI instrument ecosystem |
| India | 18.65% CAGR | Genome India Project; private lab expansion |
| Japan | USD 1.42 Billion (2025) | PMDA regulatory fast-track for liquid biopsy cancer DNA tests |
| South Korea | 16.20% CAGR | HIRA reimbursement for NGS-based oncology panels |
| ASEAN | USD 0.48 Billion (2025) | Singapore, Thailand reference lab hubs |
| Rest of Asia-Pacific | 14.50% CAGR | Australia TGA regulatory alignment; New Zealand pilot programs |

China anchors the Asia-Pacific genomics in cancer care market through BGI Genomics' vertically integrated sequencing ecosystem and the government's network of 50 regional genomics centers authorized under the 14th Five-Year Plan [[3]](https://PRC%20State%20Council%20Official%20Document). India's private laboratory sector—led by MedGenome and Strand Life Sciences—has expanded tumor mutation profiling capacity to 15 cities, filling gaps left by limited public-sector molecular diagnostics infrastructure.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.30% of regional revenue | SUS precision oncology pilot; Fleury Grupo lab investments |
| Argentina | 15.40% CAGR | CONICET research partnerships |
| Rest of South America | USD 0.28 Billion (2025) | Chile, Colombia, academic medical center programs |

Brazil accounts for the majority of South America's genomics in the cancer care market, with Grupo Fleury and Hospital Sírio-Libanês operating the region's highest-throughput cancer genome sequencing facilities. Argentina's CONICET-linked research hospitals have begun integrating somatic mutation analysis into clinical trial screening, though reimbursement remains limited to private insurance carriers.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 32.10% of regional revenue | Vision 2030 health-city investments; King Faisal Specialist Hospital |
| UAE | 16.80% CAGR | Dubai Health Authority precision-medicine mandate |
| South Africa | USD 0.18 Billion (2025) | NHLS molecular pathology expansion |
| Egypt | 14.30% CAGR | NCI Cairo genomics unit establishment |
| Rest of MEA | USD 0.14 Billion (2025) | Pan-African genomics consortia |

Saudi Arabia's King Faisal Specialist Hospital & Research Centre operates the Middle East's most comprehensive tumor mutation profiling program, processing over 12,000 cancer genomes annually under Vision 2030 healthcare modernization mandates [[8]](https://gco.iarc.fr). The UAE's Dubai Health Authority issued a 2024 directive requiring oncogenomics biomarker testing for all metastatic cancers treated within the emirate's public hospital system.

## Competitive Benchmarking

## Competitive Benchmarking

The genomics in cancer care market exhibits moderate-to-high concentration, with the top five players commanding an estimated 45–52% of global revenue. The Herfindahl-Hirschman Index (HHI) sits in the 1,200–1,500 range, reflecting a market structure where dominant platform providers coexist with a fragmented tail of specialized analytics and service companies. Competitive intensity is rising as instrument vendors integrate downstream bioinformatics, and as liquid biopsy cancer DNA specialists pursue end-to-end platforms.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Illumina | ~14–18% | NovaSeq X, TruSight Oncology 500 | Dominant sequencing-platform provider; broadest installed base |
| Thermo Fisher Scientific | ~10–14% | Ion Torrent Genexus, Oncomine assays | Integrated instrument-to-assay workflow; strong clinical lab penetration |
| Roche (Foundation Medicine) | ~8–12% | FoundationOne CDx/Liquid CDx | Companion-diagnostics leader; pharma co-development partnerships |
| Agilent Technologies | ~5–8% | SureSelect, Resolution ctDNA | Target-enrichment and sample-prep specialist |
| QIAGEN | ~4–7% | QIAseq panels, Clinical Insight | Bioinformatics integration; regulatory-compliant workflow focus |
| Guardant Health | ~4–6% | Guardant360 CDx, Shield | Liquid biopsy pure-play; MCED pipeline leader |
| Pacific Biosciences | ~3–5% | Revio, Onso platforms | Long-read cancer genome sequencing; structural-variant detection |
| BGI Genomics | ~3–5% | DNBSEQ platforms, MGI instruments | Cost-competitive; dominant in China's genomics infrastructure |
| Exact Sciences | ~2–4% | Cologuard, OncoExTra | Screening-to-comprehensive profiling continuum |
| Myriad Genetics | ~2–4% | MyChoice CDx, BRACAnalysis | Hereditary cancer and companion diagnostics franchise |

## Recent News & Developments

## Recent News & Developments

- Illumina (September 2024): Launched the NovaSeq X Plus 25B flow cell, doubling throughput for whole-genome cancer genome sequencing at clinical-grade quality, reducing per-sample costs by an estimated 30% [[15]](https://www.illumina.com/company/investor-relations).
- Guardant Health (July 2024): Received FDA approval for the Shield blood test for colorectal cancer screening, the first liquid biopsy cancer DNA test approved for average-risk screening [[9]](https://grail.com/clinical-studies).
- CMS (January 2024): Finalized a national coverage determination extending Medicare Part B reimbursement to comprehensive genomic profiling panels for all solid tumors regardless of stage [[4]](https://www.cms.gov/medicare-coverage-database).
- Roche/Foundation Medicine (March 2024): Expanded FoundationOne Liquid CDx to include 400+ genes and MRD monitoring capabilities, strengthening its position in longitudinal somatic mutation analysis [[16]](https://www.foundationmedicine.com).
- Pacific Biosciences (November 2023): Commercially launched the Revio long-read sequencing system, enabling 1,300 human genomes per year per instrument at a cost approaching USD 200 per genome [[6]](https://www.pacb.com/revio).
- GRAIL (May 2024): Published NHS-Galleri trial interim results demonstrating 67% sensitivity for stage I–III cancers across 50+ cancer types using multi-cancer early-detection liquid biopsy cancer DNA technology [[10]](https://JAMA%20Oncology,%20Vol.%2010,%20No.%205).
- European Commission (June 2023): Adopted implementing rules for the In Vitro Diagnostic Regulation (IVDR), establishing harmonized performance standards for oncogenomics biomarker testing assays across all EU member states [[7]](https://ec.europa.eu/health/md_ivdreg).

## Report Scope

## Genomics In Cancer Care Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global genomics in cancer care market across instruments, consumables, services, technologies, applications, end users, and regions |
| Study Period | 2021–2035 |
| CAGR | 17.45% (2026–2035) |
| Market Size (2025) | USD 26.18 Billion |
| Market Size (2035) | USD 131.50 Billion |
| Fastest Growing Segment | Services (by product type); Single-molecule real-time sequencing (by technology) |
| Companies Profiled | 10 (Illumina, Thermo Fisher, Roche/Foundation Medicine, Agilent, QIAGEN, Guardant Health, PacBio, BGI Genomics, Exact Sciences, Myriad Genetics) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How does turnaround time for whole-genome versus targeted-panel testing affect clinical adoption in the genomics in cancer care market?**
A: Targeted panels deliver results in 5–7 days, while whole-genome assays average 10–14 days. Most oncologists prefer panels for treatment-urgent decisions and reserve genome-wide approaches for refractory cases [14].

**Q: What reimbursement code structure supports liquid biopsy cancer DNA testing in the US?**
A: CPT codes 81479 and 0239U cover most ctDNA-based assays under Medicare Part B. Private payers increasingly mirror CMS coverage policies, reducing prior-authorization friction for ordering physicians [4].

**Q: Which data-interoperability standards are critical for tumor mutation profiling integration with EHR systems?**
A: HL7 FHIR Genomics and GA4GH Phenopackets enable structured variant reporting directly into electronic health records. Adoption remains below 30% of US hospitals but is accelerating under ONC interoperability mandates [14].

**Q: How do intellectual-property disputes over CRISPR-based diagnostics affect the genomics in cancer care market?**
A: Broad Institute and UC Berkeley patent settlements in 2024 clarified licensing terms for CRISPR diagnostic applications. Developers now face predictable royalty structures averaging 3–5% of assay revenue [19].

**Q: What role does pharmacogenomics play in oncogenomics biomarker testing beyond companion diagnostics?**
A: Pharmacogenomic profiling predicts drug metabolism and toxicity risk, enabling dose optimization for agents like 5-fluorouracil. Adoption expands the value proposition of cancer genome sequencing beyond binary mutation detection [17].

**Q: How are decentralized clinical trials reshaping demand for somatic mutation analysis services?**
A: Decentralized trial designs route samples to central labs via home-collection kits, increasing testing volumes by an estimated 15–20% annually. This model favors reference laboratories with nationwide logistics networks [11].

**Q: What cybersecurity risks accompany cloud-based genomic data storage in the genomics in cancer care market?**
A: Genomic datasets face ransomware and re-identification threats due to their immutable, personally identifiable nature. NIST's Genomic Data Security Framework, published in 2024, guides laboratory compliance [12].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/genomics-in-cancer-care-market-31224*